Fig. 9.

CCR2 antagonism improved glycemic control in mice on a HFD with CCR2. Glycemic control was assessed at the beginning and end of the treatment period with glucose tolerance tests and insulin challenges. Mice in each group showed similar responses at the start of the treatment period [glucose (A) and insulin (D)]. At the time of death, mice treated with CCX872 showed significantly improved response to glucose and insulin (B and E, respectively). When assessed by measuring area under the curve, statistically significant changes were seen [glucose (C) and insulin (F)]. ***P < 0.001 by Student’s t-test.